Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
A Phase 1b, Age De-Escalation/Dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in an African Population of Adults and Children in a Setting of Perennial Malaria Transmission
Gates Medical Research Institute
123 participants
Mar 28, 2025
INTERVENTIONAL
Conditions
Summary
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common. Part A is an open-label study conducted in healthy adults whereas Part B is double-blind study conducted in young children and infants. Both the parts will evaluate the safety, tolerability and pharmacokinetics of MAM01.
Eligibility
Inclusion Criteria14
- PART A
- Male or female adults aged 18 to 55 years inclusive at the time of signing the informed consent form (ICF), who are capable of, and willing to provide, informed consent
- Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
- All dosing groups: hemoglobin level ≥ 8 grams per deciliter (g/dL)
- All dosing groups: living within local jurisdiction of trial site(s) and available for the duration of the trial for all cohorts
- Female participants of childbearing potential must be nonpregnant and agree to avoid becoming pregnant by using an acceptable contraception method
- PART B
- Age Cohort 2: male or female children aged 2 years to <5 years at the time their parent or Legally Authorized Representative (LAR) signs the ICF
- Age Cohort 3: male or female children aged 12 months to <24 months at the time their parent or LAR signs the ICF
- Age Cohort 4: male or female infant children aged 3 months to <12 months and weighing at least 5 kilograms (kg) at the time their parent or LAR signs the ICF
- Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
- Hemoglobin level ≥ 8g/dL
- Height and weight Z-scores ≥-2
- Living within local jurisdiction of trial site(s) and available for the duration of the trial
Exclusion Criteria17
- PART A \& PART B
- Within 48 hours prior to randomization, acute febrile illness
- Sickle cell disease or history of splenectomy
- Use of antimalarial chemoprevention or treatment, and/or antibiotics with known antimalarial effects (eg, clotrimoxazole, azithromycin, tetracyclines) within 30 days prior to dosing
- Enrolled in another clinical trial within 90 days prior to Screening or planning to participate in another trial during, or within 1 year following, their participation in this trial
- Received any doses of a malaria vaccine or other monoclonal antibodies (mAb) to Pf
- Eligible to receive a malaria vaccine (RTS, S/AS01 or R21/Matrix-M) at screening or if it is expected to become available during the period of the trial.
- History of allergy or hypersensitivity or contraindications to trial drugs (including those used as empirically treatment for Pf to clear any existing parasitemia), excipients or related substances
- Any history of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the trial
- History of any autoimmune disease or immunodeficiency or other impairment to the immune system, including HIV infection
- Use of chronic (≥ 14 days) immunosuppressive agents including systemic steroids (eg, prednisone >10 milligrams per day \[mg/day\]) within 30 days prior to dosing. Use of inhaled or topical corticosteroids is permitted
- Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising with blood draws
- Receipt of immunoglobulins and/or blood products within the past 6 months
- Any current uncontrolled medical or psychiatric condition, or substance abuse problems that in the opinion of the Investigator, will make it unlikely for participant to comply with the protocol, may interfere with study assessments, or could jeopardize the safety of the participant
- Any contraindication for a subcutaneous injection, intravenous injection, or intramuscular injection, as applicable
- For Part A, female participants who are breastfeeding, pregnant, or unable or unwilling to adhere to required contraception
- For Part B, in the opinion of the Investigator, the parent or LAR may not be able to ensure participant compliance with the requirements of the trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MAM01 300 mg will be administered SC
MAM01 300 mg will be administered IM route
MAM01 2000 mg will be administered IV
MAM01 190 mg will be administered SC
MAM01 225 mg will be administered SC
MAM01 150 mg will be administered SC
MAM01 150 mg will be administered IM
MAM01 150 mg will be administered IV
Placebo will be administered SC
Placebo will be administered IV.
Placebo will be administered IM
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06408857